RMD - ResMed Inc.
NYSE
->
Healthcare
->
Medical Instruments & Supplies
San Diego,
United States
Type: Equity
RMD price evolution
RMD
| (in millions $) | 31 Jan 2025 | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $238.36 | $237.91 | ||
| Short term investments | ||||
| Net receivables | $855.03 | $837.27 | $779.26 | |
| Inventory | $917.98 | $822.25 | $829.46 | |
| Total current assets | $2641.13 | $2357.72 | $2351.3 | |
| Long term investments | ||||
| Property, plant & equipment | $717.28 | $699.15 | $686.82 | |
| Goodwill & intangible assets | $3327.96 | $3337.02 | ||
| Total noncurrent assets | $4514.68 | $4463.27 | ||
| Total investments | ||||
| Total assets | $7222.42 | $6872.39 | $6814.56 | |
| Current liabilities | ||||
| Accounts payable | $249.28 | $237.73 | $177.44 | |
| Deferred revenue | $289.9 | $282.73 | ||
| Short long term debt | $35.18 | $34.09 | ||
| Total current liabilities | $904.08 | $910.65 | $773.03 | |
| Long term debt | $667.58 | $838.76 | $1133.36 | |
| Total noncurrent liabilities | $1097.7 | $1411.61 | ||
| Total debt | $873.93 | $1167.44 | ||
| Total liabilities | $2027.39 | $2008.35 | $2184.64 | |
| Shareholders' equity | ||||
| Retained earnings | $5225.11 | $4991.65 | $4769.96 | |
| Other shareholder equity | -$132.16 | -$251.53 | -$265.31 | |
| Total shareholder equity | $4864.04 | $4629.92 | ||
| (in millions $) | 31 Jan 2025 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $238.36 | $227.89 | $273.71 | $295.28 |
| Short term investments | ||||
| Net receivables | $837.27 | $704.91 | $575.95 | $614.29 |
| Inventory | $822.25 | $998.01 | $743.91 | $457.03 |
| Total current assets | $2357.72 | $2367.83 | $1931.48 | $1574.76 |
| Long term investments | ||||
| Property, plant & equipment | $699.15 | $665.81 | $630.5 | $592.07 |
| Goodwill & intangible assets | $3327.96 | $3322.64 | $2282.39 | $2320.48 |
| Total noncurrent assets | $4514.68 | $4383.88 | $3164.38 | $3153.37 |
| Total investments | ||||
| Total assets | $6872.39 | $6751.71 | $5095.85 | $4728.13 |
| Current liabilities | ||||
| Accounts payable | $237.73 | $150.76 | $159.25 | $138.01 |
| Deferred revenue | $289.9 | $257.26 | $204.12 | $201.11 |
| Short long term debt | $35.18 | $31.82 | $31.77 | $35.59 |
| Total current liabilities | $910.65 | $758.53 | $689.3 | $911.77 |
| Long term debt | $838.76 | $1548.09 | $885.78 | $758.13 |
| Total noncurrent liabilities | $1097.7 | $1863.27 | $1045.8 | $930.68 |
| Total debt | $873.93 | $1579.91 | $917.55 | $793.72 |
| Total liabilities | $2008.35 | $2621.8 | $1735.1 | $1842.45 |
| Shareholders' equity | ||||
| Retained earnings | $4991.65 | $4253.02 | $3613.74 | $3079.64 |
| Other shareholder equity | -$251.53 | -$272.53 | -$312.75 | -$193.49 |
| Total shareholder equity | $4864.04 | $4129.9 | $3360.75 | $2885.68 |
| (in millions $) | 31 Jan 2025 | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1196.98 | |||
| Cost of revenue | $504.2 | |||
| Gross Profit | $692.78 | |||
| Operating activities | ||||
| Research & development | $77.07 | |||
| Selling, general & administrative | $229.92 | |||
| Total operating expenses | $318.2 | |||
| Operating income | $374.58 | |||
| Income from continuing operations | ||||
| EBIT | $386.45 | |||
| Income tax expense | $74.93 | |||
| Interest expense | $11.03 | |||
| Net income | ||||
| Net income | $300.49 | |||
| Income (for common shares) | $300.49 | |||
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4685.3 | $4222.99 | $3578.13 | $3196.82 |
| Cost of revenue | $2029.99 | $1867.33 | $1553.82 | $1357.72 |
| Gross Profit | $2655.3 | $2355.66 | $2024.31 | $1839.1 |
| Operating activities | ||||
| Research & development | $307.52 | $287.64 | $253.57 | $225.28 |
| Selling, general & administrative | $917.14 | $874 | $739.37 | $670.39 |
| Total operating expenses | $1335.41 | $1223.79 | $1024.03 | $935.42 |
| Operating income | $1319.89 | $1131.87 | $1000.29 | $903.68 |
| Income from continuing operations | ||||
| EBIT | $1310.51 | $1149.04 | $982.79 | $907.65 |
| Income tax expense | $243.85 | $204.11 | $181.05 | $409.16 |
| Interest expense | $45.71 | $47.38 | $22.31 | $23.99 |
| Net income | ||||
| Net income | $1020.95 | $897.56 | $779.44 | $474.5 |
| Income (for common shares) | $1020.95 | $897.56 | $779.44 | $474.5 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $292.24 | $300.49 | $208.8 | |
| Operating activities | ||||
| Depreciation | $54.76 | $54.64 | $53.37 | |
| Business acquisitions & disposals | -$19.7 | -$3.08 | -$7.5 | |
| Stock-based compensation | $21.39 | $20.44 | $19.84 | |
| Total cash flows from operations | $440.11 | $402.03 | $272.83 | |
| Investing activities | ||||
| Capital expenditures | -$24.88 | -$21.19 | -$23.35 | |
| Investments | -$0.49 | -$6.96 | -$9.08 | |
| Total cash flows from investing | $2.15 | -$46.51 | -$33.15 | -$41.14 |
| Financing activities | ||||
| Dividends paid | -$77.89 | -$70.55 | -$70.49 | -$70.68 |
| Sale and purchase of stock | -$22.31 | -$45.11 | -$30.48 | |
| Net borrowings | -$300 | -$220 | -$130 | |
| Total cash flows from financing | -$150.76 | -$393.28 | -$335.91 | -$238.96 |
| Effect of exchange rate | $11.07 | $0.13 | -$5.3 | $8.42 |
| Change in cash and equivalents | $188 | $0.45 | $27.66 | $1.15 |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | $1020.95 | $897.56 | $779.44 | $474.5 |
| Operating activities | ||||
| Depreciation | $216.21 | $197.56 | $193.84 | $191.52 |
| Business acquisitions & disposals | -$133.46 | -$1012.75 | -$42.78 | -$39.07 |
| Stock-based compensation | $80.18 | $71.14 | $65.26 | $63.93 |
| Total cash flows from operations | $1401.26 | $693.3 | $351.15 | $736.72 |
| Investing activities | ||||
| Capital expenditures | -$99.46 | -$119.67 | -$134.84 | -$102.71 |
| Investments | -$21.46 | -$13.1 | -$31.1 | -$2.57 |
| Total cash flows from investing | -$269.78 | -$1159.85 | -$229.92 | -$158.46 |
| Financing activities | ||||
| Dividends paid | -$282.32 | -$258.28 | -$245.34 | -$226.71 |
| Sale and purchase of stock | -$96.92 | $49.14 | $47.38 | $37.79 |
| Net borrowings | -$730 | $665 | $122 | -$522 |
| Total cash flows from financing | -$1119.29 | $422.87 | -$128.36 | -$764.63 |
| Effect of exchange rate | -$1.72 | -$2.15 | -$14.43 | $18.5 |
| Change in cash and equivalents | $10.47 | -$45.82 | -$21.57 | -$167.88 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.41 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |